|

DC/MM Fusion Vaccine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Dendritic Cell/Tumor Fusion Vaccine

Pipeline

Phase 1: 1

Top Sponsors

  • David Avigan1

Indications

  • Relapse Multiple Myeloma1
  • Refractory Multiple Myeloma1
  • Multiple Myeloma1
  • Cancer1

Boston, Massachusetts1 trial

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Beth Israel Deaconess Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.